As the clinical research landscape for cell and gene therapies evolves beyond oncology, the autoimmune disease space is emerging as a compelling frontier, rich with opportunity yet fraught with complexity. Unlike oncology, where therapies target malignant cells, autoimmune conditions require a nuanced approach rooted in immunology to modulate the immune system without compromising its essential functions.

A New Era of Biotech Innovation

Autoimmune diseases present a unique challenge: treatments must target specific immune pathways while preserving overall immune function. For example, B-cell therapies may reduce disease activity, but long-lived plasma cells can sustain inflammation. Addressing these complexities demands data-driven decisions, early planning, and a deep understanding of personalized medicine.

The Insight Brief highlights how sponsors, investigators and healthcare professionals must collaborate as cross-functional teams to navigate this evolving therapeutic landscape.

Clinical Trial Strategy for Sponsors

Sponsors are tasked with designing trials that balance scientific rigor with operational feasibility. Autoimmune trials often involve personalized treatment plans, long-term follow-up and multiple endpoints. Adaptive trial design and real-world evidence can help optimize efficiency while maintaining regulatory compliance.

Early engagement with regulators is essential. Autoimmune therapies may follow different approval pathways than oncology treatments, requiring sponsors to align expectations and anticipate global requirements such as Institutional Biosafety Committee (IBC) approvals and Good Clinical Practice (GCP) standards.

Site Readiness and Investigator Support

Investigators and clinical sites are central to trial success. Unlike oncology centers, autoimmune trials require coordination between CAR-T therapy specialists and disease-specific experts such as rheumatologists or neurologists. Site readiness including training, clear protocols and logistical support is critical.

Operational complexity is heightened by the need for cold chain management, chain of custody and specialized infrastructure. Sponsors can support sites by streamlining procedures and investing in resources that reduce burden and improve operational excellence.

"This shift is more than just a trend—it’s reflected in the increasing number of clinical trials dedicated to autoimmune diseases. Once dominated by oncology, the pipeline is now seeing a surge in non-oncology studies, particularly in autoimmune research. This evolution speaks to the broader dynamics in the industry, as investors, sponsors and clinicians actively explore new opportunities in this space."

Patient Engagement with Purpose

Patients with autoimmune diseases often face chronic symptoms and long-term treatment burdens. Engaging them in clinical trials requires empathy and flexibility. Transparent communication, travel support and home health services can improve recruitment and retention. Patient engagement strategies like clinical trial educators help patients understand the risks and benefits of participation.

Unlike oncology patients, autoimmune participants may be more cautious about immunosuppression and long-term side effects. Sponsors must tailor messaging and trial design to reflect these concerns.

Commercialization Strategy Starts Early

Commercial teams must begin planning well before product launch. Understanding market access dynamics, anticipating competition and engaging payers early are key to success. Demonstrating long-term value and cost-effectiveness will be essential for securing reimbursement and driving adoption.

In our Insight Brief, experts emphasize that commercialization strategy is not a final step, it’s an integral part of the development lifecycle. Early alignment between clinical and commercial teams ensures a smoother transition from trial to market.

A Unified Playbook for All Stakeholders

An integrated approach that brings together sponsors, investigators, healthcare professionals and commercial teams. By aligning strategy early and leveraging cross-functional expertise, stakeholders can accelerate biotech innovation and improve outcomes.

IQVIA Biotech is investing in global site networks, training programs and service solutions to support this evolution. Our commitment to operational excellence and patient engagement positions them as a key partner in advancing autoimmune CAGT.

Conclusion: Turning Complexity into Opportunity

Cell and gene therapy holds transformative potential for autoimmune disease. But realizing this promise requires more than scientific innovation, it demands strategic foresight, clinical development expertise and a deep understanding of the patient journey. This Insight Brief, written by experts from IQVIA Biotech and IQVIA, provides information for stakeholders interested in advancing CAGT in autoimmune indications and outlines strategic considerations for progress in this field.

By embracing complexity and building a unified playbook, the industry can unlock new possibilities for patients and redefine the future of autoimmune treatment.

Want more? Watch the webinar presentation on-demand.

Let’s connect. We want to help sponsors navigate operational challenges specific to cell and gene therapy trials.